MTOR and mucositis: A significant proportion (n = 14, 60.9%) of patients on mTOR inhibitors experienced adverse events (Supplementary Table S2), most common of which was oral mucositis or ulcer (n = 8, 34.8%), followed by infection (n = 4, 17.4%).